BEAM THERAPEUTICS INC. - COMMON STOCK

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

14 May 2025 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

13 May 2025 04:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

12 May 2025 13:01:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

06 May 2025 04:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

05 Apr 2025 04:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

27 Mar 2025 13:01:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Pricing of Underwritten Offering

10 Mar 2025 03:01:26 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

10 Mar 2025 03:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

25 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

24 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

30 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

23 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

13 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

17 Dec 2024 04:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

08 Dec 2024 10:45:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

07 Dec 2024 08:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

06 Dec 2024 04:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

04 Dec 2024 04:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

12 Nov 2024 13:01:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

05 Nov 2024 06:00:00 By Nasdaq GlobeNewswire